Evaluation of the effect of Loigolactobacillus coryniformis K8 CECT 5711 consumption in health care workers exposed to COVID-19

Ethics statement The studies involving human participants were reviewed and approved by the Regional Ethical Committee (Granada, Spain). The patients/participants provided their written informed consent to participate in this study. Author contributions RR-B and MO participated in the conception of the study, designed the methodology, and contributed to the manuscript writing. JS-G participated in the design of the study and critically revised the manuscript. ÁC-V and AA recruited and followed-up the volunteers. JM-L provided study materials and performed the data curation. RB-R participated in the study design, analyzed the data, interpreted the results, and wrote the draft of the manuscript. All authors have read and approved the final manuscript. Conflict of interest JM-L, MO, and RB-R are workers of Biosearch Life, a Kerry Company, owner of the patent of Loigolactobacillus coryniformis CECT 5711. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Publisher's note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. Supplementary material The..